In the second trial loss for Johnson & Johnson’s talc products in as many months, a jury in Los Angeles ordered the company and other defendants to pay $25.75 million in damages to plaintiff Joanne Anderson.
Anderson sued J&J and its co-defendants alleging the company’s Baby Powder contains asbestos and caused her mesothelioma, a type of lung cancer linked with the substance. The jury originally handed down compensatory damages of $21.75 million after trial, and followed that up on Thursday with an award of $4 million in punitive damages, according to Androvett Legal Media. J&J is liable for two-thirds of the verdict amount.
A J&J spokesperson said the company is “disappointed with the verdict and we will begin the appeals process.” The company will “continue to defend the safety of our product because it does not contain asbestos or cause mesothelioma,” she added.
Nintedanib is a new generation of oral drugs for the treatment of cancer and idiopathic pulmonary fibrosis. It is a triple angiogeninase inhibitor that can simultaneously inhibit the three main receptors for angiogenesis and tumor growth. The main receptors include vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR).
Selumetinib (AZD6244) is a drug that was discovered by Array BioPharma and was licensed to AstraZeneca. It is being investigated for the treatment of various types of cancer, such as non-small cell lung cancer (NSCLC).
This is Accel Pharmtech, LLC (DUNS number: 833130128)and we welcome all customers and vendors to cooperate business with us to achieve the greatest mutual benefits!
In a sweeping success for cancer immunotherapy this year, the U.S. Food & Drug Administration approved the first two treatments that use a patient’s own genetically engineered cells to combat specific kinds of blood cancer.
Both new drugs are CAR T-cell immunotherapies, created by injecting an individual’s T cells with DNA that encodes a chimeric antigen receptor (CAR). The CAR proteins jut from the immune cells’ surfaces and direct them to seek and destroy tumor cells.
CAR-T is state of the art, and this is just the beginning.
In a deal worth up to $1.5 billion, Bayer and Loxo Oncology will jointly develop two Loxo drug candidates, larotrectinib and LOXO-195, for treating cancers caused by a rare genetic mutation.
Larotrectinib was a breakout star of the American Society for Clinical Oncology conference in June, where researchers revealed that it shrank tumors in 76% of the kids and adults in a small study. LOXO-195, currently in Phase I/II trials, is designed to treat people who develop resistance to first-generation TRK inhibitors like larotrectinib.
Now, Bayer, which some investors view as a second-tier player in oncology, will split U.S. marketing responsibilities with Loxo.
Olaparib (AZD-2281, trade name Lynparza) is an FDA-approved targeted therapy for cancer, developed by KuDOS Pharmaceuticals and later by AstraZeneca. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.
Elesclomol (INN, codenamed STA-4783) is a drug that triggers apoptosis (programmed cell death) in cancer cells. It is being developed by Synta Pharmaceuticals and GlaxoSmithKline as a chemotherapy adjuvant, and has received both fast track and orphan drug status from the U.S. Food and Drug Administration for the treatment of metastatic melanoma. CAS# 488832-69-5
If you have any problems, please feel free to contact us. ♥♥♥